Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System

NCT01751308 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01751308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01751308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2013
Completion date
February 29, 2016
Enrollment
39 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumor - malignant nervous system neoplasm